© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
April 20, 2016
Is a methacetin breath test superior to MELD scores in predicting mortality in liver failure?
Being overweight in itself is a risk factor for non-alcoholic fatty liver disease (NAFLD), but people of normal body mass index (BMI) can have lean NAFLD and if so they are in even greater danger.
April 19, 2016
Severe neurological symptoms, not liver failure, should be the signal to start thinking about a liver transplant in Wilson Disease, French researchers say.
An Australian physician is sending generic DAAs made in China and India to patients with hepatitis in the US. It's part of an NIH-approved clinical trial.
April 18, 2016
Liver transplant does not always mean the end of a hepatitis infection. A California team has had success treating recurrent HCV with DAAs.
Public health concerns in Europe mount as data show Syrian refugees have higher rates of HBV than residents in host countries.
Delivering on predictions made at major liver disease meetings over the past year, researchers said two experimental panvirals are curing hepatitis patients who had not been helped by earlier direct-acting antivirals.
April 16, 2016
In what researchers said was the first study of DAAs in children with HCV, UK researchers reported the drugs were effective and well tolerated. Questions remain about whther they might have any negative effects farther out.
A team from Germany found patients with acute HCV infection could be cured in six weeks with DAA treatment, half the recommended time.
The best treatment so far for primary sclerosing cholangitis, a rare and devastating inflammatory disease that typically strikes people in late adolescence or early adulthood, is liver transplant. But a phase 2 trial of norursodeoxycholic acid showed efficacy.